SEC Form 4 · accession 0001179110-17-015442
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur J Higgins
Officer — President and CEO · Director
Period of report
Dec 14, 2017
Accepted (ET)
Dec 15, 2017 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2017 | P | 75,000 | $8.16 | A | 111,760 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F2,F3 | — | Dec 14, 2017 | A | 73,529 | A | — | Dec 14, 2027 | Common Stock | 73,529 | 73,529 | D |
Explanation of responses
- F1Amount excludes 1,000 shares of common stock held indirectly by Child but includes 15,000 shares held indirectly by Family Trust.
- F2Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F3These restricted stock units are scheduled to fully vest on December 5, 2020, assuming continued employment through the applicable vesting date.
- F4These Restricted Stock Units were granted pursuant to the one-time incentive program for the Company's Chief Executive Officer which was approved by the Board on December 6, 2017.